Hannah Furney, APRN
Adult Health · Las Vegas, NVNPI 1740727007
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,187 of the $1,629 with a category attached, or 72.9%. It is spread thinly across 24 manufacturers, the largest accounting for just 11.2%. Reporting peaked in 2022 at $1,174 and has fallen 75.3% since, to $290 in 2025.
Across 58 payments — averaging $28.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$183
- Sobi, Inc$158
- Johnson & Johnson$144
- Amgen$132
- Seagen Inc.$124
- Astellas Pharma US Inc$117
- plus $769 from 18 others
Across 1 payment — averaging $29,329 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$29K
What the payments were for
- Food & beverage$1,18773%
- Education$44227%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 9 | $183 |
| Sobi, Inc | 2 | $158 |
| Johnson & Johnson | 3 | $144 |
| Amgen | 7 | $132 |
| Seagen Inc. | 3 | $124 |
| Astellas Pharma US Inc | 4 | $117 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Incyte Corporation | 2 | $87 |
| Regeneron Healthcare Solutions, Inc. | 3 | $71 |
| AstraZeneca | 3 | $63 |
| Sanofi | 2 | $60 |
| Novartis | 3 | $58 |
| EMD Serono, Inc. | 3 | $50 |
| Bristol Myers Squibb | 2 | $46 |
| Merck | 2 | $39 |
| Karyopharm Therapeutics Inc. | 1 | $33 |
| Taiho Oncology, Inc. | 1 | $33 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Genmab U.S., Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $18 |
| GSK | 1 | $12 |
How this compares
$1,629 in reported general payments places this provider in the 70th percentile of 90 adult health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 22 | $409,930 |
| CalquenceAcalabrutinib Maleate | 19 | $244,207 |
| LynparzaOlaparib | 12 | $214,316 |
| SprycelDasatinib | 11 | $193,599 |
| EliquisApixaban | 53 | $40,665 |
| XareltoRivaroxaban | 23 | $19,043 |
| Abiraterone Acetate | 27 | $3,015 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 56 | $2,400 |
| Letrozole | 88 | $1,823 |
| Ondansetron OdtOndansetron | 40 | $1,560 |
| Morphine Sulfate ErMorphine Sulfate | 27 | $942 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 23 | $929 |
| Ondansetron Hcl | 27 | $766 |
| Anastrozole | 59 | $682 |
| Oxycodone Hcl | 47 | $658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Lynparza | $63 | $458,52331 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $23 | $409,93022 claims |
| Johnson & JohnsonXarelto | $144 | $19,04323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 90 adult health providers in Nevada.
Other adult health in Las Vegas
- Marcia Castro-RosenbergLas Vegas$64K
- Amanda SquiersLas Vegas$36K
- Jasmina FornbacherLas Vegas$14K
- Marcella PomeranzLas Vegas$14K
- Karisa SonLas Vegas$10K
- Jessica LuceroLas Vegas$6K
- Monica LynamLas Vegas$5K
- Thomas McNeilLas Vegas$5K
- Roger ConantLas Vegas$4K
- Ruth RamirezLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.